 |
| 鄭佳瑋 |
 |
| 王志豪 |
 |
| 蔡佩姍 |
 |
| 郭瑋庭 |
 |
| 程吉安 |
 |
| 吳孟儒 |
【2021 BTBA Dec Workshop】The Journey from Postdoc to PI
Are you interested in a career in academia but still have doubts or questions? Come and hear from our group of panelists, who will share their first-hand experiences of what an academic life looks like when transitioning from postdoc to PI!
𝗧𝗶𝗺𝗲: Dec 11 (Sat), 10-11:30 am (EST) 11-12:30 pm (Taiwan Time) 𝗣𝗹𝗮𝗰𝗲: Online event via Zoom 𝗦𝗽𝗲𝗮𝗸𝗲𝗿:❖ Chia-Wei Cheng, Assistant Professor at Columbia University Irving Medical Center
❖ Chih-Hao Wang, Assistant Professor at Graduate Institute of Biomedical Sciences, China Medical University
❖ Erica Cai, Assistant Investigator in the Lilly Diabetes Center of Excellence at the Indiana Biosciences Research Institute
❖ Wei-Ting Kuo, Assistant Professor at Graduate Institute of Oral Biology, College of Medicine, National Taiwan University
❖ Chih-Hao Wang, Assistant Professor at Graduate Institute of Biomedical Sciences, China Medical University
❖ Erica Cai, Assistant Investigator in the Lilly Diabetes Center of Excellence at the Indiana Biosciences Research Institute
❖ Wei-Ting Kuo, Assistant Professor at Graduate Institute of Oral Biology, College of Medicine, National Taiwan University
𝗠𝗼𝗱𝗲𝗿𝗮𝘁𝗼𝗿:❖ Annie Cheng, Postdoctoral research fellow, Brigham and Women’s Hospital, Wyss Institute
❖ Meng-Ju Wu, Postdoctoral research fellow, Massachusetts General Hospital Cancer Center
❖ Meng-Ju Wu, Postdoctoral research fellow, Massachusetts General Hospital Cancer Center
-
是不是對於PI這個職位還有很多想問的問題呢？我們都聽到你的心聲了！BTBA一口氣邀請到四位，分別在美國及台灣學術界擔任PI的優秀學者齊聚一堂。將在短短一個半小時中，不藏私地與大家分享當上PI前後的心境轉折、需要克服的困難等等，絕對滿足你對於美國及台灣學術界的好奇心，還有可能會聽到一些網路上搜尋不到的學術界小秘密喔！
如果你正佇足於學術界與業界的交叉路口，別再猶豫了！快來報名參加BTBA 12月的線上學術專題論壇：從博後變身為PI的心路歷程大分享。
時間: 12月11日 (日) 上午十點 (東岸時間); 晚上十一點 (台灣時間) 地點: Online event via Zoom 講者:❖ 鄭佳瑋: Assistant Professor at Columbia University Irving Medical Center
❖ 王志豪: 助理教授, 中國醫藥大學醫學院-生物醫學研究所
❖ 蔡佩珊: Assistant Investigator, Lilly Diabetes Center of Excellence at the Indiana Biosciences Research Institute
❖ 郭瑋庭: 助理教授, 台灣大學醫學院-口腔生物科學研究所
❖ 王志豪: 助理教授, 中國醫藥大學醫學院-生物醫學研究所
❖ 蔡佩珊: Assistant Investigator, Lilly Diabetes Center of Excellence at the Indiana Biosciences Research Institute
❖ 郭瑋庭: 助理教授, 台灣大學醫學院-口腔生物科學研究所
主持人:❖ 程吉安, 博士後研究人員, 布萊根婦女醫院及Wyss Institute
❖ 吳孟儒, 博士後研究人員, 麻省總醫院癌症中心
❖ 吳孟儒, 博士後研究人員, 麻省總醫院癌症中心
-
【Speaker】
CHIA-WEI CHENG 鄭佳瑋
Dr. Cheng conducted her doctoral research in Dr. Valter D. Longo's laboratory at the University of Southern California (USC). She completed her postdoctoral training in Dr. Omer H. Yilmaz's laboratory at Koch Institute at Massachusetts Institute of Technology (MIT). Dr. Cheng was a fellow of Helen Hay Whitney Foundation (HHWF) and is an awardee of the NIH Pathway to Independence Award (K99), with Dr. David M. Sabatini's co-mentorship. Earlier this year, Dr. Cheng joined Columbia University Irving Medical Center (CUIMC) as an assistant professor in the Department of Genetics and Development (G&D) and Columbia Stem Cell Initiative (CSCI). Her Lab studies the molecular machinery that translates nutritional cues into cell-fate determinants. Her goal is to decipher the nutrigenomic underpinning of stem cell identity in the hopes of inspiring new therapeutic strategies.
Dr. Cheng conducted her doctoral research in Dr. Valter D. Longo's laboratory at the University of Southern California (USC). She completed her postdoctoral training in Dr. Omer H. Yilmaz's laboratory at Koch Institute at Massachusetts Institute of Technology (MIT). Dr. Cheng was a fellow of Helen Hay Whitney Foundation (HHWF) and is an awardee of the NIH Pathway to Independence Award (K99), with Dr. David M. Sabatini's co-mentorship. Earlier this year, Dr. Cheng joined Columbia University Irving Medical Center (CUIMC) as an assistant professor in the Department of Genetics and Development (G&D) and Columbia Stem Cell Initiative (CSCI). Her Lab studies the molecular machinery that translates nutritional cues into cell-fate determinants. Her goal is to decipher the nutrigenomic underpinning of stem cell identity in the hopes of inspiring new therapeutic strategies.
LinkedIn: https://www.linkedin.com/in/chia-wei-cheng-6103771a
Lab intro: https://www.stemcell.columbia.edu/csci-member-spotlight-blog
Lab website: https://www.stemcell.columbia.edu/research-labs/cheng-lab
Lab twitter: @Chenglab_CSCI
Lab intro: https://www.stemcell.columbia.edu/csci-member-spotlight-blog
Lab website: https://www.stemcell.columbia.edu/research-labs/cheng-lab
Lab twitter: @Chenglab_CSCI
-
CHIH-HAO WANG 王志豪
Dr. Wang received his Ph.D. degree in Taiwan and finished his postdoctoral training at Joslin Diabetes Center, Harvard Medical School, Boston, USA. He is currently an assistant professor in the Graduate Institute of Biomedical Sciences at China Medical University, Taichung, Taiwan. His research focuses on using pharmacological and genetic approaches to activate brown fat and/or white fat browning and investigating the underlying mechanisms. His ultimate research goal is to apply those basic scientific findings to regulate whole-body energy metabolism for the treatment of obesity, diabetes, and metabolic disorders.
Dr. Wang received his Ph.D. degree in Taiwan and finished his postdoctoral training at Joslin Diabetes Center, Harvard Medical School, Boston, USA. He is currently an assistant professor in the Graduate Institute of Biomedical Sciences at China Medical University, Taichung, Taiwan. His research focuses on using pharmacological and genetic approaches to activate brown fat and/or white fat browning and investigating the underlying mechanisms. His ultimate research goal is to apply those basic scientific findings to regulate whole-body energy metabolism for the treatment of obesity, diabetes, and metabolic disorders.
LinkedIn: https://www.linkedin.com/in/chih-hao-wang-16496371/
ResearchGate: https://www.researchgate.net/profile/Chih-Hao-Wang-3
Lab website: http://webap.cmu.edu.tw/TchEportfolio/index_1/chih-haowang
ResearchGate: https://www.researchgate.net/profile/Chih-Hao-Wang-3
Lab website: http://webap.cmu.edu.tw/TchEportfolio/index_1/chih-haowang
-
ERICA CAI 蔡佩珊
Erica Cai, PhD, obtained her bachelor’s degree in medical technology from Taipei Medical University and her master’s degree in biochemistry and molecular biology from National Taiwan University. She was trained by Dr. Minna Woo and received her Ph.D. in medical science from the University of Toronto, Canada.
Cai was an instructor in medicine at the Harvard Medical School. She worked in the laboratory of Dr. Peng Yi and the CRISPR screen core facility at the Joslin Diabetes Center. Her research projects used a multidisciplinary approach to investigate beta-cell physiology, including cell regeneration, cell function, stress response, and autoimmune protection. Dr. Cai joined the Lilly Diabetes Center of Excellence within the IBRI Diabetes Center in April 2021. She also is a member of the Indiana University Center for Diabetes and Metabolic Diseases. Cai’s current research focuses on beta-cell protection and diabetes prevention. Her ultimate research goal is to better understand diseases and help improve patients' quality of life.
Erica Cai, PhD, obtained her bachelor’s degree in medical technology from Taipei Medical University and her master’s degree in biochemistry and molecular biology from National Taiwan University. She was trained by Dr. Minna Woo and received her Ph.D. in medical science from the University of Toronto, Canada.
Cai was an instructor in medicine at the Harvard Medical School. She worked in the laboratory of Dr. Peng Yi and the CRISPR screen core facility at the Joslin Diabetes Center. Her research projects used a multidisciplinary approach to investigate beta-cell physiology, including cell regeneration, cell function, stress response, and autoimmune protection. Dr. Cai joined the Lilly Diabetes Center of Excellence within the IBRI Diabetes Center in April 2021. She also is a member of the Indiana University Center for Diabetes and Metabolic Diseases. Cai’s current research focuses on beta-cell protection and diabetes prevention. Her ultimate research goal is to better understand diseases and help improve patients' quality of life.
LinkedIn: https://www.linkedin.com/in/ericapcai/
Lab website: https://www.indianabiosciences.org/ericacailab
Lab website: https://www.indianabiosciences.org/ericacailab
-
WEI-TING KUO 郭瑋庭
Dr. Kuo is an assistant professor in the Graduate Institute of Oral Biology, College of Medicine, National Taiwan University. His laboratory investigates the physiological and pathological mechanisms of tight junction (TJ) protein regulation in epithelial organisms and mucosal homeostasis. Their research interests focus on the role of TJ proteins in mucosal repair and cancer pathogenesis.
Dr. Kuo is an assistant professor in the Graduate Institute of Oral Biology, College of Medicine, National Taiwan University. His laboratory investigates the physiological and pathological mechanisms of tight junction (TJ) protein regulation in epithelial organisms and mucosal homeostasis. Their research interests focus on the role of TJ proteins in mucosal repair and cancer pathogenesis.
【Moderator】
CHI-AN (ANNIE) CHENG 程吉安
Dr. Annie Cheng obtained her bachelor’s and master’s degrees in chemistry from National Taiwan University. She was trained by Dr. Jeffrey Zink and received her Ph.D. in bioengineering from the University of California, Los Angeles (UCLA). During her Ph.D. training, she was awarded the UCLA Dissertation Year Fellowship. Annie is now a postdoctoral research fellow at Brigham and Women’s Hospital of Harvard Medical School and Wyss Institute. Since the COVID-19 pandemic, her research has focused on COVID-19 serology studies such as COVID-19 vaccine evaluation.
Dr. Annie Cheng obtained her bachelor’s and master’s degrees in chemistry from National Taiwan University. She was trained by Dr. Jeffrey Zink and received her Ph.D. in bioengineering from the University of California, Los Angeles (UCLA). During her Ph.D. training, she was awarded the UCLA Dissertation Year Fellowship. Annie is now a postdoctoral research fellow at Brigham and Women’s Hospital of Harvard Medical School and Wyss Institute. Since the COVID-19 pandemic, her research has focused on COVID-19 serology studies such as COVID-19 vaccine evaluation.
-
MENG-JU WU 吳孟儒
Dr. Meng-Ju Wu obtained his bachelor’s and master’s degrees from National Yang-Ming University. He conducted his doctoral research in Dr. Alice Chang’s laboratory at Purdue University. Meng-Ju is now a postdoctoral fellow of the American Cancer Society (ACS) with Dr. Nabeel Bardeesy and Dr. Robert Manguso's co-mentorship at Massachusetts General Hospital (MGH). His research focuses on how tumor metabolism affects tumorigenesis and the tumor microenvironment.
Dr. Meng-Ju Wu obtained his bachelor’s and master’s degrees from National Yang-Ming University. He conducted his doctoral research in Dr. Alice Chang’s laboratory at Purdue University. Meng-Ju is now a postdoctoral fellow of the American Cancer Society (ACS) with Dr. Nabeel Bardeesy and Dr. Robert Manguso's co-mentorship at Massachusetts General Hospital (MGH). His research focuses on how tumor metabolism affects tumorigenesis and the tumor microenvironment.
LinkedIn: https://www.linkedin.com/in/meng-ju-wu
【【 BTBA Special Event】曲速行動的背後 - COVID19醫藥品全球開發供應的考量
***此次演講將實體進行，不開放錄音和錄影***
為應變COVID-19全球大流行，多國皆在過去一年多致力於COVID-19疫苗與藥品的開發，如何兼顧安全、效用以及速度是疫苗開發需要面對的挑戰。BTBA很榮幸邀請到Greenberg Traurig資深合夥律師–呂家鋒與大家分享在過去一年多COVID-19疫苗和藥品的開發和商業化過程的考量。演講中，呂律師將提供其第一線參與曲速行動的觀察，他將解釋美國決定採取曲速行動的來由，以及其代表廠商參與跟國家及超國家組織的談判中如何建構產品的供應和採購的過程。
時間： 12/11 (Sat) 2:00PM - 4:00PM (EST) 地點：Mount Auburn Room, 2F, Harvard Smith Campus Center
(1350 Massachusetts Ave, Cambridge, MA 02138)
報名表:：https://forms.gle/dfzuteXCV5ZCnyCK8*因活動場地有人數限制及考量活動主題，本活動將優先開放給於業界或健康政策相關領域人士參與，再依報名順序依次遞補。主辦單位將於活動前寄送通知信給報名成功者。若不克參與，請聯絡主辦單位以便讓候補者參加。
活動流程：2:00-2:05 主持人開場、介紹講者
2:05-3:05 呂律師經驗分享
3:05-3:35 Q & A時間
3:35-4:00 Networking
講者：呂家鋒 (Chia-Feng Lu) 律師 (Greenberg Traurig 國際法律事務所 資深合夥人) 主持人：杜荷洲 (Ho-Chou Tu) 博士 (Associate Director at Alnylam Pharmaceuticals) 特別感謝：哈佛大學台灣學生會、駐波士頓科技組協助本活動的舉辦。-------------------------------------------------------------------
【呂家鋒律師】
為全球知名Greenberg Traurig國際法律事務所華盛頓特區及東京辦公室的資深合夥人。他提供從事生命科學和新興技術公司、產業協會諮詢，引領他們了解適用於其產品、技術、服務和業務策略的監管和交易法規。呂律師代表客戶參與政府法律相關的管理策略以及法規流程的制定，並提供政府部門相關政策擬定的建議. 其並協助客戶擬定策略計劃，幫助其產品與創新能夠在現行或未來的政策和法律架構下落實,譬如,藥品定價,市場核准進入,和供應。呂律師提供創投、私募基金，及生命科學公司在企業發展、醫藥法規策略、併購和策略合作、法規遵循、產品生命週期管理、藥價設定談判的法律諮詢，協助企業將商業策略落實在跨國法律政策的架構下。呂律師代表新興科技公司和生技領域的領導廠商在各個領域，例如細胞治療、癌症免疫治療、人工智慧/物聯網產品、微生物產品、精準醫療產品及服務、再生醫學、3D列印等。呂律師至少曾為三個基於諾貝爾科學獎得獎的產品提供諮詢，其中一項已在市場上成為重磅藥品。呂律師更為多個政府組織提供新興科技的政策與立法管理的諮詢。在學界部分,除了曾在幾間大學醫學院和商學院授課外，呂律師對於亞洲人才的培育十分有熱忱及使命，過去幾年持續擔任日本京都大學醫學院的兼任教師。
【杜荷洲博士】
於Washington University in St. Louis取得Molecular & Cell Biology博士學位，她的博士論文研究在正常與癌細胞中不同的細胞死亡機制。其後，杜博士於Boston Children's Hospital/Harvard Medical School接受博士後訓練，研究幹細胞因子在實質腫瘤 (solid tumor) 的發生與進展過程扮演的角色。2015年，杜博士加入Alnylam Pharmaceuticals，其為帶領世界級生技領域發展RNAi治療平台的公司，包括於2018年第一個被FDA核准的RNAi治療藥物。目前Alnylam Pharmaceuticals的產線有四個商業化的計劃以及超過十個臨床階段的計劃。杜博士在Next Wave" Liver group 帶領跨領域的團隊加強並拓展Alnylam未來的肝臟藥物產品線。杜博士更擔任數個臨床前期及臨床階段計劃的研究負責人，專攻非酒精性脂性肝炎(nonalcoholic steatohepatitis, NASH) 、心血管代謝及罕見疾病。
LinkedIn: https://www.linkedin.com/in/ho-chou-tu/
See less
沒有留言:
發佈留言